Wit, F. et al. Three-year extended follow-up of the 2NN study: a randomised comparative trial of first-line antiretroviral therapy with regimens containing either nevirapine, efavirenz or both drugs combined, together with stavudine and lamivudine. 4th International AIDS Society (IAS) Conference on HIV Pathogenesis and Treatment; Sydney, Australia. Abstract #WEPEB032
Sankatsing, R. et al. Nevirapine increases High Density Lipoprotein-cholesterol by stimulation of apolipoprotein AI synthesis. 4th International AIDS Society (IAS) conference on HIV Pathogenesis and Treatment; Sydney, Australia. Abstract #WEPEB120LB
(i) The U.S. Centers for Disease Control and Prevention (CDC) disease
staging system assesses the severity of HIV disease by CD4 cell
counts and by the presence of specific HIV-related conditions.
Category B events are symptomatic conditions of HIV infection in
adolescents or adults. Category C events are AIDS-indicator
conditions, such as recurrent bacterial pneumonia, coccidioidomycosis
and histoplasmosis. (Source: AIDS Education and Training Centers
(AETC) National Resource Center)
Web site: http://www.boehringer-ingelheim.com/hiv
Judith von Gordon, CD Communications, Boehringer Ingelheim +49-61-32-77-3582, or fax: +49-61-32-77-6601